Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy

Health Technology Assessment

Volumn 10, Issue 34, 2006, Pages 1-153

  Williams, C ^a   Brunskill, S ^b   Altman, D ^c   Briggs, A ^d   Campbell, H ^e   Clarke, M ^f   Glanville, J ^g   Gray, A ^e   Harris, A ^h   Johnston, K ⁱ   Lodge, M ^j  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^g UNIVERSITY OF YORK   (United Kingdom)

^h CHURCHILL HOSPITAL   (United Kingdom)

ⁱ Economics and Statistics Division   (United Kingdom)

^j WOLFSON COLLEGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CATHEPSIN D; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; MYC PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN PS2; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UROKINASE;

ANEUPLOIDY; APOPTOSIS; ARTICLE; BODY SIZE; BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION SUPPORT SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; EARLY CANCER; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS; METHODOLOGY; MINIMAL RESIDUAL DISEASE; OUTCOMES RESEARCH; PARAMETRIC TEST; PATIENT SELECTION; PLOIDY; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; QUALITATIVE RESEARCH; QUALITY CONTROL; QUALITY OF LIFE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT PLANNING; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

EID: 33750534179     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10340     Document Type: Article

References (286)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52-.23-47.
2. DOH 2002 NHS Cancer Screening Programmes. [Cancer Screening Programmes]. URL: www.cancerscreening.nhs.uk. Accessed 6 September 2002.
3. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166.
4. American Cancer Society. [Breast cancer facts and figures]. URL: www.cancer.org. Accessed 6 September 2002.
5. Forbes JE Breast cancer. In Williams CJ, editor. Evidence-based oncology. London: BMJ Books; 2003.
6. Brown P. UK death rates from breast cancer fall by a third. BMJ 2000;321:849.
7. Early Breast Cancer Thalists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988;319:1681-92.
8. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer, volume 1: worldwide evidence 1985-1990. Oxford: Oxford University Press; 1990.
9. Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 3 1,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71-85.
10. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials. N Engl J Med 1995;333:1444-55.
11. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96.
12. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:930-42.
13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
14. Early Breast Cancer Trialists' Collaborative Group. Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717.
15. Haagensen CD, Stout AP. Carcinoma of the breast: criteria of operability. Ann Surg 1969; 118:859-70, 1032-51.
16. Crile G. In Stoll BA, editor. Breast cancer management: early and late. London: Heinemann; 1977.
17. Saeki T What is the Japanese consensus on adjuvant chemotherapy in breast cancer? Breast Cancer 2003;10:15-20.
18. Ravdin PM. How can prognostic and predictive factors in breast cancer be used in a practical way today? Recent Results Cancer Res 1998; 152:86-93.
19. St Gallen Consensus Conference. J Clin Oncol 2001;19:5817-27.
20. NIH Consensus Statement 114. Adjuvant therapy for breast cancer. November 1-3 2000;17:1-23.
21. American Society of Clinical Oncology Expert Panel. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology Expert Panel. J Clin Oncol 1996; 14:2843-77.
22. American Society of Clinical Oncology. 2000 update of recommendations for the use of tumour markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol 2001;19:1865-78.
23. Borghouts JA, Koes BW, Bouter LM. The clinical course and prognostic factors of non-specific neck pain: a systematic review. Pain 1998;77:1-13.
24. Carson CA, Fine MJ, Smith MA, Weissfeld LA, Huber JT Kapoor WN. Quality of published reports of the prognosis of community-acquired pneumonia.J Gen Intern Med 1994;9:13-19.
25. Cole MG, Bellavance F. Depression in elderly medical inpatients- a meta-analysis of outcomes. Can Med Assoc J 1997; 157:1055-60.
26. Davies HT Crombie IK. Bias in cohort studies. Hosp Med 2000;61:133-5.
27. Delgado-Rodriguez M. [Biases in the study of prognostic factors], Med Clin 1999;112(Suppi 1): 51-8.
28. Laupacis A, Wells G, Richardson WS, Tugwell P. Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA 1994;272:234-7.
29. Levine MN, Brownian GP, Gent M, Roberts R, Goodyear M. When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 199 1; 9:348-56.
30. Look MP. Pooled analysis of uPA and PAI-I for prognosis in primary breast cancer patients. EORTC Receptor and Biomarker Study Group. Int J Biol Markers 2000; 15:70-2.
31. Lucassen PL, Assendelft WJ, van Eijk JT, Gubbels JW, Douwes AC, van Geldrop WJ. Systematic review of the occurrence of infantile colic in the community. Arch Dis Child 2001;84:398-403.
32. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640-6.
33. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35.
34. O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronail heart disease events in asymptomatic populations. Am J Cardiol 2000;85:945-8.
35. Randolph AG, Guyatt GH, Richardson WS. Prognosis in the intensive care unit: finding accurate and useful estimates for counseling patients. Crit Care Med 1998;26:767-72.
36. Steinberg EP, Eknoyan G, Levin NW, Eschbach JW, Golper TA, Owen WE et al. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: description, findings, and implications. Am J Kidney Dis 2000;36: 1-11.
37. Vance RP, Elevitch FR. College of American Pathologists Foundation Conference VIII on patient-centered pathology practice-outcomes and accountability. Overview, glossary, and bibliograp Arch Pathol Lab Med 1997; 121:1151-62.
38. Yarbro JW, Page DL, Yielding LP, Partridge EE, Murphy GP. American joint Committee on Cancer prognostic factors consensus conference. Cancer 1999;86:2436-46.
39. Zarbo RJ. The oncologic pathology report. Quality by design. Arch Pathol Lab Med 2000;124:1004-10.
40. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
41. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Nat Cancer Inst 1991; 83:154-5.
42. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
43. Altman DG. Systematic reviews of evaluations of prognostic variables. In Egger M, Davey SG, Altman DG, editors. Systematic reviews in health care. Meta-analysis in context. London: BMJ Books; 2001. pp. 228-47
44. Kernan W-N, Feinstein AR, Brass LM. A methodological appraisal of research on prognosis after transient ischemic attacks. Stroke 1991;22:1108-16.
45. Hudak PL, Cole DC, Haines AT. Understanding prognosis to improve rehabilitation: the example of lateral elbow pain. Arch Phys Med Rehabil 1996; 77:586-93.
46. Marx BE, Marx M. Prognosis of idiopathic membranous nephropathy: a methodologic meta-analysis. Kidney Int 1997;51:873-9.
47. Straus SE, McAlister EA. A clinician's guide to journal articles about prognosis. ACP J Club 1999; 130:AI3-15.
48. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001;323:224-8.
49. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der MeulenJHP, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.
50. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.
51. Fayers PM, Machin D. Sample size: how many patients are necessary? Br J Cancer 1995;72:1-9.
52. Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 2000; 19:441-52.
53. Bentzen SM. Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys 2001;49:513-18.
54. Song F, Eastwood AJ, Gilbody S, Dulcy L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4(l0).
55. Simon R. Evaluating prognostic factor studies. In Gospodarowicz MK, Henson DE, Hutter RVP, et al., editors. Prognostic factors in cancer. New York: Wiley-Liss; 2001.
56. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
57. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-36.
58. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998;105: 836-48.
59. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Research and Treatment 1998;52:289-303.
60. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191-8.
61. Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy. A meta-analysis. JAMA 2000;284:1417-24.
62. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. A decade of progress. Chest 2002;122:1037-57.
63. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17:2815-34.
64. Cohen J. The cost of dichotomization. Appl Psychol Meas 1983;7:249-53.
65. Morgan TM, Elashoff FA. Effect of categorizing a continuous covariate on the comparison of survival time. J Am Stat Assoc 1986;81:917-21.
66. Altman DG, Lausen B, Sauerbrei W. Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 1994;86:829-35.
67. Vollmer RT, Seigler HE Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. Am J Clin Pathol 2001;115:205-12.
68. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992;22:197-206.
69. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M, the German Breast Cancer Study Group (GBSG). Modelling the effects of standard prognostic factors in node-positive breast cancer. Stat Med 1999;79:1752-60.
70. Buettner P, Garbe C, Guggenmoos-Holzmann I. Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol 1997;50:1201-10.
71. Steels E, Paesmans M, Berghmans T, Branle E, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18:705-19.
72. Greenland S. A critical look at some popular meta-analytic methods. Am J Epidemial 1994; 140:290-6.
73. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
74. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511-18.
75. Andersen PK. Survival analysis 1982-1991: the second decade of the proportional hazards regression model. Stat Med 199 1; 10: 1931-41.
76. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendation for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.
77. Cuzick J. Interaction, subgroup analysis and sample size. IARC Sci Publ 1999; 109-21.
78. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey SG. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5(33).
79. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21:2917-30.
80. Royston P, Sauerbrei W, Ritchie A. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 2004; 90:794-9.
81. Schmitz-DrAger BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Eur Urol 2000;38:691-700.
82. Burke HB, Henson DE. Specimen banks for cancer prognostic factor research. Arch Pathol Lab Med 1998;122:871-4.
83. Mirza AN, Mirza NQ Vlastos G, Singletary SE. Prognostic factors in node-ncgative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235:10-26.
84. Porter-Jordan K, Lippman ME. Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 1994;8:73-100.
85. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29:41-9.
86. Klijn JG, Berns PM, Schmitz PI, Fockens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer. a review on 5232 patients. Endocr Rev 1992;13:3-17.
87. Révillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34:791-808.
88. Ross JS. The HER-2/neu gene and protein in breast cancer: methods of detection and clinical significance. J Clin Ligand Assay 2000;23:21-32.
89. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002;3:125-35.
90. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998;52:261-88.
91. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688-95.
92. Berns EMJJ, Kljn JGM, van Staveren IL, Portengen H, Noordegraaf E, Fbekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/ neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992;28:697-700.
93. Wenger CR, Clark GM. S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 1998;51:255-65.
94. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Nat Cancer Inst Monogr 2001;30:27-35.
95. Sunderland MC, McGuire WL. Prognoitic indicators in invasive breast cancer. Surg Cli North Am 1990;70:989-1004.
96. Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: a review of the literature involving over 9000 patients. Appl Immunohistochem 1996; 4:106-16.
97. Elledge RM, Allred DC. Prognostic significance of p53 gene alterations in node negative breast cancer. Breast Cancer Res Treat 1998;52:79-98.
98. Pharoah PDP, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breasi cancer: a meta-analysis. Br J Cancer 1999;80:1968-73.
99. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Nat Cancer Inst 1993;85:965-70.
100. Elledge RM, Fuqua SA, Clarck GM. Prognostic significance of p53 gene alterations in node negative breast cancer. Breast Cancer Res Treat 1993;26:225-35.
101. Iacopetta B, Grieu F, Pbwell B. Analysis of p53 gene mutation by polymerase chain reaction - single strand confirmation polymorphism provides independent prognostic information in node- negative breast cancer. Clin Cancer Res 1998; 4:1597-602.
102. Domagala W, Welcker M, Chosia M. p2 I/WAF/Cip I expression in invasive ductal breast carcinoma: relationship to p53, proliferation rate, and survival at 5 years. Virchows Arch 2001;439:132-40.
103. Zhang G-J, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (review). Oncol Rep 1998;5:1211-16.
104. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 1997;76:661-6.
105. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, et al. Association between high concentrations of Mr 52,000 D and poor prognosis in primary human breast cancer. Cancer Res 1989;49:6008-14.
106. Tandon AR, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
107. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11: 36-43.
108. Namer M, Ramaioli A, Fontana X. Prognostic value of total cathepsin D in breast tumours: a possible role in selection of chemoresistant patients. Breast Cancer Res Treat 199 1; 19:85-93.
109. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79:300-307.
110. Henry JA, McCarthy AL, Angus B. Prognostic significance of the estrogen regulated protein cathepsin D in breast cancer: an inummohistochemical study. Cancer 1990; 65:265-71.
111. Look MP, Fockens JA. Clinical relevance of the urokinase plasminogen activator system in breast cancer. Acta Pathol, Microbiol Immunol Scand 1999; 107:150-9.
112. Harbeck N, Kruger A, Sinz S. Clinical relevance of the plasminogen activator inhibitor type I - a multifaceted proteolytic factor. Onkologie 2001; 24:238-44.
113. Look MP, van Putten WL, Dufry MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pboled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI- I in 8377 breast cancer patients. J Nat Cancer Inst 2002;94:116-28.
114. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60:636-43.
115. Funke I, Schraut W, Meta-analysis of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated. J Clin Oncol 1998;16:557-66.
116. Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev 2000;26:53-65.
117. Singletery SE, Larry L, Tucker S. Detection of micrometastatic tumour cells in bone marrow of breast carcinoma patients. J Surg Oncol 1991; 47:32-6.
118. Diel IJ, Kaufmann M, Costa SD. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Clin Oncol 1996;88:1652-64.
119. Merkle E, Baehr J, Henke A, Buelmer M, Martus P [Immunocytochemical detection of tumor cells in bone marrow as a prognostic factor in breast carcinoma]. Geburtshilfe und Frauenheilkunde 1994; 54:662-9.
120. Chen Y-Y, Schnitt SJ. Prognostic factors for patients with breast cancer 1 cm and smaller. Breast Cancer Res Treat 1998;51:209-25.
121. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
122. Goodwin PJ, Boyd NE Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat 1990;16:205-14.
123. Stewart LA, Clarke MJ, for the Cochrane Collaboration Working Group on Meta-analysis Using Individual Patient Data. Practical methodology of meta-analysis (overviews) using updated individual patient data. Stat Med 1995; 14:2057-79.
124. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000; 19:453-73.
125. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994; 30:117-26.
126. Cooke T, Reeves J, Lannigan A, Stanton P. The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker. Eur J Cancer 2001;37:3-10.
127. Chan CM, Baratta FS, Ozzeilo L, Ceriani RL. Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 1994;30:243-61.
128. Burstein AH. Fracture classification systems: do they work and are they useful? T J Bone Joint Surg Am Vol 1993;75:1743-4.
129. Wyatt JC, Altman DG. Commentary: prognostic models: clinically useful or quickly forgotten? BMJ 1995;311:1539-41.
130. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Validity of prognostic models: when is a model clinically useful? Semin Urol Oncol 2002;20:96-107.
131. Tarassenko L, Whitehouse R, Gasparini G, Harris AL. Neural network prediction of relapse in breast cancer. Neural Comput Appl 1996; 4:105-13.
132. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariate models. Ann Intern Med 1993; 118:210.
133. Schumacher M, Holländer N, Schwarzer G, Sauerbrei W, Prognostic factor studies. In Crowley J, editor. Handbook of statistics in clinical oncology. New York: Marcel Dekker; 2001. pp. 321-78.
134. Concato J. Challenges in prognostic analysis. Cancer (Suppl) 2001;91:1607-14.
135. Burke HB, Henson DE. The American joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131-5.
136. Redelmeier DA, Lustig AJ. Prognostic indices in clinical practice. JAMA 2001;285:3024-5.
137. McShane LM, Simon R. Statistical methods for the analysis of prognostic factor studies. In Gospodarowicz MK, Henson DE, Hutter RVP, et al. editors. Prognostic factors in cancer. New York: Wiley-Liss; 2001. pp. 37-48.
138. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985;69:1071-7.
139. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503-10.
140. Feinstein AR. Multivariable analysis: an introduction. New Haven, CT- Yale University Press; 1996.
141. Clark TG, Altman DG. Developing a prognostic model in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol 2003;56: 28-37.
142. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002;12:1-6.
143. Vach W Some issues in estimating the effect of prognostic factors from incomplete covariate data. Stat Med 1997;16:57-72.
144. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15.
145. Burton A, Altman D. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 2004;91:4-8.
146. Altman DG. Suboptimal analysis using 'optimal' cutpoints. Br J Cancer 1998;78:556-7.
147. Bossard N, Descotes F, Bremond AG, Bobin Y, De Saint Hilaire P, Golfier F, et al. Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer. Breast Cancer Res Treat 2003; 82:47-59.
148. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part 11: multivariate data analysis - an introduction to concepts and methods. Br J Cancer 2003;89:431-6.
149. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992;11:2093-109.
150. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175-97.
151. Nardi A, Schemper M. Comparing Cox and parametric models in clinical studies. Stat Med 2003;22:3597-610.
152. LeBlanc M. Tree-based methods for prognostic stratification. In Crowley J, editor. Handbook of statistics in clinical oncology. New York: Marcel Dekker; 2001. pp. 457-72.
153. Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 2003;26:172-81.
154. Erlichman C, Warde P, Gadalla T, Ciampi A, Baskerville T. RECPAM analysis of prognostic factors in patients with stage III breast cancer. Breast Cancer Res Treat 1990;16:231-42.
155. Ripley RM, Harris AL, Tarassenko L. Neural network models for breast cancer prognosis. Neural Comput Appl 1998;7:367-75.
156. Rodvold DM, McLeod DG, Brandt JM, Snow PB, Murphy GP. Artificial neural networks for physicians: a technology introduction. In Gospodarowicz MK, Henson DE, Hutter RVP, et al., editors. Prognostic factors in cancer. New York: Wiley-Liss; 2001. pp. 57-70.
157. Biganzoli E, Boracchi P, Daidone MG, Gion M, Marubini E. Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998;13:107-23.
158. Sargent DJ. Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 2001;91:1636-42.
159. Schwarzer G, Vach W, Schumacher M. On the misuses of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med 2000; 19:541-61.
160. Schwarzer G, Schumacher M. Artificial neural networks for diagnosis and prognosis in prostate cancer. Semin Urol Oncol 2002;20:89-95.
161. Elston EW, Ellis IO. Method for grading breast cancer. J Clin Pathol 1993;46:189-90.
162. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004;23:723-48.
163. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-77.
164. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004; 328:39-41.
165. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323: 42-6.
166. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project Protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71:2507-14.
167. Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast car-cinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001;91:1679-87.
168. Chapman JA, Trudeau ME, Pritchard KI, Sawka CA, Mobbs BG, Hanna WM, et al. A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. Breast Cancer Res Treat 1992;22:263-72.
169. Blarney RW. The design and clinical use of the Nottingham prognostic index in breast cancer. Breast 1996;5:156-7.
170. Burke HB, Rosen DB, Goodman PH. Comparing the prediction accuracy of artificial neural networks and other statistical models for breast cancer survival. In Tesauro G, et al., editors. Advances in neural information processing systems 7. Cambridge, MA: MIT Press; 1995. pp. 1063-7.
171. Clark G, Hilsenbeck SG, Ravdin PM, Osborne CK. Validation of a model that identifies high risk breast cancer patients for clinical trials of intensive therapy (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995;14:92.
172. De Laurendis M, Ravdin PM, Clark GM. Prognostic models for producing numerical estimates of disease free survival of breast cancer patients (meeting abstract). Breast Cancer Res Treat 1993;27:181.
173. Denic S. Three-dimensional survival model of breast cancer patients. Anticancer Res 1996; 16:3217-19.
174. Frkovic-Grazio S, Bracko M. Long term prognostic value of Nottingham histological grade and its components in early (pTINOMO) breast carcinoma. J Clin Pathol 2002;55:88-92.
175. Grumett SA, Snow PB. Artificial neural networks: a new model for assessing prognostic factors. Ann Oncol 2000;11:383-4.
176. Hasebe T Mukai K, Tsuda H, Ochiai A. New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus. Pathol Int 2000; 50:263-72.
177. Knox W, Walls J, Donne A, Wallis N, Redford J, Swindell R, et al. The prognostic value of full axillary node clearance (meeting abstract). J Pathol 1993;170:384A.
178. Marchevsky AM, Shah S, Patel S. Reasoning with uncertainty in pathology: artificial neural networks and logistic regression as tools for prediction of lymph node status in breast cancer patients. Mod Pathol 1999;12:505-13.
179. Pinder SE, Murray S, Ellis IO, Tribia H, Elston CW, Gelber RD, et al.
180. Quantin C, Moreau T Asselain B, Maccario J, Lellouch J. A regression survival model for testing the proportional hazards hypothesis. Biometrics 1996;52:874-85.
181. Rostgaard K, Mouridsen HT, Vaeth M, Holst H, Olesen KP, Lynge E. A modified Nottingham prognostic index for breast cancer patients diagnosed in Denmark 1978-1994. Acta Oncol 2001;40:838-43.
182. Rudolph P, Alm P, Heidebrecht HJ, Bolte R, Ratjen V Baldetorp B, et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Nat Cancer Inst 1999;91:2713-18.
183. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401-8.
184. Guerra I, Algorta J, Diaz dO, Pelayo A, Farina J. Immumnohistochemical prognostic index for breast cancer in young women. Mot Pathol 2003;56:323-7.
185. Lundin M, Lundin J, Burke HB, Toikkanen S, Piylkkanen L, Joensuu H. Artificial neural networks applied to survival prediction in breast cancer A. Oncology 1999;57:281-6.
186. Kaufmann M, Minckwitz VG, Finn HP Schmid H, Goerttler K, Bastert G. Combination of grading and new biological factors (S-phase fraction and epidermal growth factor receptor) can predict relapse and survival in patients with node-negative primary breast cancer. Onkologie 1994;17:166-72.
187. Collan Y, Kumpusalo L, Pesonen E, Eskelinen M, Pajarinen P, Kettimen K. Prediction of survival in breast cancer: evaluation of different multivariate models. Anticancer Res 1998;18:647-50.
188. Burke HB, Goodman PH, Rosen DB, Henson DE, Weinstein JN, Harrell FE Jr, et al. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 1997;79:857-62.
189. Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 1999;84:203-8.
190. Baak JPA, Van Dop H, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56:374-82.
191. Knorr KL, Hilsenbeck SG, Wenger CR, Pounds G, Oldaker T, Vendely P, et al. Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat 1992;22:251-62.
192. Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 199 1;68:2142-9.
193. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC. A prognostic index in primary breast cancer. Br J Cancer 1982;45:361-6.
194. Blamey RW, Davies CJ, Elston CW, Johnson J, Haybittle JL, Maynard PV. Prognostic factors in breast cancer - the formation of a prognostic index. Clin Oncol 1979;5:227-36.
195. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11:359-77.
196. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92.
197. Galea MH, Blarney RW, Elston CW, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22: 207-19.
198. De Laurendis M, De Placido S, Bianco AR, Clark GM, Ravdin PM. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin Cancer Res 1999;5:4133-9.
199. Albain KS, Green S, LeBlanc M, Rivkin S, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adJuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat 1992; 22:273-84.
200. Anderson TJ, Alexander FE, Lamb J, Smith A, Forrest AP. Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 2000;83:487-92.
201. Aubele M, Auer G, Voss A, Falkmer U, Rutquist L, Hoefler H. Disease-free survival of node-positive breast cancer patients. Improved prognostication by cytometrical parameters. Pathol Res Pract 1995;191:982-90.
202. Bryan RM, Mercer RJ, Bennett RC, Rennie GC. Prognostic factors in breast cancer and the development of a prognostic index. Br J Surg 1986;73:267-71.
203. Caleffi M, Fentiman IS, Birkhead BG. Factors at presentation influencing the prognosis in breast cancer. Eur J Cancer Clin Oncol 1989;25:51-6.
204. Ceriani RL, Chan CM, Baratta FS, Ozzello L, DeRosa CM, Habif DV. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int J Cancer 1992;51:343-54.
205. Chan CM, Baratta FS, Ozzello L, Ceriani RL. Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carrinoma of the breast. Breast Cancer Res Treat 1994;30:243-61.
206. Chapman JW, Hanna W, Kahn HJ, Lickley HL, Wall J, Fish EB, et al. Altemative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone. Surg Oncol 1996;5:265-71.
207. Chevallier B, Mosseri V, Dance JP, Bastit P, Julien JP, Asselain B. A prognostic score in histological node negative breast cancer. Br J Cancer 1990;61:436-40.
208. Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to piimary breast cancer. Cancer 1993;71:2157-62.
209. Coradini D, Boracchi P Daidone MG, Pellizzaro C, Miodini P Ammatuna M, et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer 2001;85:795-7.
210. D'Eredita GA, Giardina C, Martellotta M, Natale T, Ferrarese F. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 2001;37:591-6.
211. Eskelinen M, Collan Y, Pajarinen P, Pesonen E, Kettimen K, Nordling S. An improved prognostic index of axillary node involvement in breast cancer incorporating DNA ploidy and tumour size. Acta Chir Scand 1990;156:521-7.
212. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer 1993;71:2141-50.
213. Fuster E, Garcia-Vilanova A, Narbona B, Romero R, Llombart-Bosch A. A statistical approach to an individualized prognostic index (IPI) for breast cancer survivability. Cancer 1983;52: 728-36.
214. Gago FE, Tello OM, Diblasi AM, Ciocca DR. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. J Steroid Biochem Mol Biol 1998;67:431-7.
215. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer 2000;82:339-47.
216. Hawkins RA, Tesdale AL, Killen ME, Jack WJ, Chetty U, Dixon J M, et al. Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 1996;74:1469-78.
217. Hawkins RA, Tesdale AL, Prescott RJ, Forster T, McIntyre MA, Baker P et al. Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index. Br J Cancer 2002;87:8-14.
218. Haybittle JL. Prognostic indices in breast cancer. Colloq Semin 1986;137:779-87.
219. Huang XE Gao F, Xue ZQ Wang Y, Xu GW. [Multifactorial analysis of survival in breast cancer]. Chung-hua Chung Liu Tsa Chih 1988; 10:117-19
220. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JFR, Blarney RW. The prognosis of small primary breast cancers. Eur J Cancer 1999; 35:908-12.
221. Korzeniowski S, Dyba T, Skolyszewski J. Classical prognostic factors for survival and loco-regional control in breast cancer patients treated with radical mastectomy alone. Acta Oncol 1994; 33:759-65.
222. McCready DR, Chapman JA, Hanna WM, Kahn HJ, Murray D, Fish EB, et al. Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model. Ann of Surg Oncol 2000;7:416-26.
223. Menard S, Bufalino R, Rilke F, Cascinelli N, Veronesi U, Colnaghi MI. Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer 1994;70:709-12.
224. Mittra I, Redkar AA, Badwe RA. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol 1995;60:106-11.
225. Parham DM, Hagen N, Brown RA. Simplified method of grading primary carcinomas of the breast. J Clin Pathol 1992;45:517-20.
226. Perrone E Carlomagno C, Lauria R, De Laurentiis M, Morabito A, Panico L, et al. Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? Eur J Cancer 1996;32A:41-6.
227. Ravdin PM, Clark GM. A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 1992;22:285-93.
228. Sauerbrei W, Hubner K, Schmoor C, Schumacher M. Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group. Breast Cancer Res Treat 1997;42:149-63.
229. Scholl S, Bieche I, Pallud C, Champeme MH, Beuvon E Hacene K, et al. Relevance of multiple biological parameters in breast cancer prognosis. Breast 1996;5:21-30.
230. Seshadri R, Horsfall DJ, McCaul K, Leong AS. A simple index to predict prognosis independent of axillary node information in breast cancer. Aust N Z J Surg 1997;67:765-70.
231. Shek LLM, Godolphin W Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 1988;48:5565-9.
232. Tubiana Hulin M, Le Doussal V Hacene K, Rouesse J, Brunet M. Sequential identification of factors predicting distant relapse in breast cancer patients treated by conservative surgery. Cancer 1993; 72:1261-71.
233. van der Linden JC, Lindeman J, Baak JP, Meijer CJ, Herman CJ. The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 1989; 10: 56-61.
234. Younes M, Lane M, Miller CC, Laucirica R. Stratified multivariate analysis of prognostic markers in breast cancer: a preliminary report. Anticancer Res 1997;17:1383-90.
235. Harbeck N, Kates R, Ulm K, Graeff H, Schmitt M. Neural network analysis of follow-up data in primary breast cancer. Int J Biol Markers 2000; 15:116-22.
236. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994;32:281-90.
237. Collett K, Skjaerven R, Maehle BO. The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat 1998;48:1-9.
238. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999;53:1-8.
239. Alexander AI, Mercer RJ, Muir IM, Bennett RC, Rennie GC. Validation of a prognostic index in breast cancer. Aust N Z J Surg 1987;57:399-403.
240. Stoll BA. Prognostic indices in breast cancer. In Stoll BA, editor. Pointers to cancer prognosis. Dordrecht: Martinus Nijhoff; 1992. pp. 195-229.
241. Vollmer RT. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Annu 1989; 24 (Pt 1):383-407.
242. Vollmer RT, Seigler HE Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma. Am J Clin. Pathol 2001;115:205-12.
243. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165:1562-8.
244. Vollmer RT, Keetch DW, Humphrey PA. Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. Cancer 1998;83:1567-80.
245. Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer 2001;91:1467-78.
246. Counsell C, Dennis M. Systematic reviews of prognostic models in patients with acute stroke. Cerebrovasc Dis 2001;12:159-70.
247. Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 2003; 39:19-30.
248. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med 1999;18:2529-45.
249. Slamon DJ, Leyland-Jones B, Shak B, Fuchs H, Paton V, Bajamonde A. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
250. Tern B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993; 55:429-35.
251. Billgren A-M, Rutqvist LE, Johansson H, Hagerstrorn T, Skoog L. The role of cathepsin D and PAI-1 in primary invasive breast cancer as prognosticators and predictors of treatment benefit with adjuvant tamoxifen. Eur J Cancer 2000;36:1374-80.
252. Tew B, Brisson J, Lapointe H, Wang CS, Bernard P, Blanchette C. Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases. Breast Cancer Res Treat 1999;55:137-47.
253. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C. Expression of cathepsin D, stromelysin-2, and urokinase by reactive stromal cells on breast carcinoma prognosis. Cancer 2001; 92:2957-64.
254. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001; 2:129-35.
255. Piccart MJ, Di Leo A, Hamilton A. HER2. a I predictive factor' ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755-61.
256. Hayes DR Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002;29:231-45.
257. Yamauchi H, Stearns V Hayes DR When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19:2334-56.
258. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p2l in breast cancer. Breast Cancer Res Treat 1998;52:79-98.
259. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647-63.
260. Calvert NW, Morgan AB, Catto JWR Hamdy FC, Akehurst RL, Mouncey P, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer 2003;88:31-5.
261. Glance LG, Osier T, Shinozaki T Intensive care unit prognostic scoring systems to predict death: a cost- effectiveness analysis. Crit Care Med 1998; 26:1842-9.
262. Hamel MB, Phillips RS, Davis RB, Desbiens N, Connors AFJ, Teno JM, et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. Ann Intern Med 1997;127:195-202.
263. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, et al. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 1994;74:3146-58.
264. Mason JM. The DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 1999; 15:173-84.
265. Drummond MR Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
266. Mikhail MG, Smith FA, Gray M, Britton C, Frederiksen SM. Cost-effectiveness of mandatory stress testing in chest pain center patients. Ann Emerg Med 1997;29:88-98.
267. Orr JWJ, Orr P, Kern DH. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 1999;5:174-88.
268. Tonnaire G. Cytogenetic and molecular biology for acute leukemias at diagnosis: a cost/effectiveness comparison. Leuk Lymphoma 1998;28:363-70.
269. Kent DM, Langa KM, Selker HP The potential use of ECG-based prognostic instruments in clinical trials and cost-effectiveness analyses of new therapies in acute cardiac ischemia. J Electrocardiol 2000;33:263-8.
270. Bast RCJ, Desch CE, Ravdin P, Smith TJ. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-77.
271. Kievit J, van de Velde CJH. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation: a Markov analysis. Cancer 1990;65:2580-7.
272. Lundin J, Lundin M, Isola J, Joensuu H. A web-based system for individualised survival estimation in breast cancer. BMJ 2003;326:29.
273. Cox DR. Note on grouping. J Am Stat Assoc 1957; 52:543-7.
274. Government Actuary Department. Interim life tables for England and Wales, women based on the years 1999-2001. London: Government Actuary Department; 2002.
275. Karnon J, Brown J. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a stochastic economic evaluation. Pharmacoeconomics 2002;20:119-37.
276. Cocquyt V, Moeremans K, Clarys P, Van Belle S, Annemans L. Postmenopausal breast cancer: incidence-based cost of illness. J Med Econ 2003; 6:15-30.
277. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
278. Cochrane manual. URL: http-//www.cocbrane.org/admin/manual.htm. Accessed 2004.
279. Haagensen CD, Cooley E. Radical mastectomy for mammary carcinoma. Ann Surg 1969;170:884-8.
280. Henderson IC, Canellos GE Cancer of the breast: the past decade (first of two parts). N Engl J Med 1980;302:17-30.
281. Halsted WS. The results of operations for the cure of cancer of the breast at the Johns Hopkins Hospital from June, 1889 to January, 1894. Johns Hopkins Hosp Bull 1907;4:1984-5.
282. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: and overview of the randomised trials. Lancet 1998; 352:930-42.
283. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
284. van der Linden JC, Baak JP, Lindeman J, Hermans J, Meyer CJ. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol 1987;40:302-6.
285. Richards M, Statham H, Green J, Murton F. Management of breast cancer. Understanding women's preconceptions. BMJ 1994;308:716.
286. Richards MA, Smith IE, Dixon JM. ABC of breast diseases. Role of systemic treatment for primary operable breast cancer. BMJ 1994;309:1363-6.